Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166675 | 0.89 | ADORA2A (0.41) | GSK3BFBP1MEN1KMT2AADORA2A | |
| SCHEMBL9125394 | 0.75 | GSK3B (0.64) | GSK3BFBP1MEN1KMT2AADORA2A | |
| SCHEMBL1167327 | 0.75 | GSK3B (0.43) | GSK3BFBP1MEN1KMT2AADORA2A | |
| SCHEMBL1969272 | 0.74 | ADORA2A (0.64) | GSK3BFBP1MEN1KMT2AADORA2A | |
| SCHEMBL1167542 | 0.74 | FBP1 (0.47) | GSK3BFBP1MEN1KMT2AADORA2A | |
| SCHEMBL1167034 | 0.74 | GSK3B (0.45) | GSK3BFBP1MEN1KMT2AADORA2A | |
| SCHEMBL1166876 | 0.73 | GSK3B (0.50) | GSK3BFBP1MEN1KMT2AADORA2A | |
| SCHEMBL1969052 | 0.73 | HCRTR2 (0.50) | GSK3BFBP1MEN1KMT2AADORA2A | |
| SCHEMBL1166205 | 0.72 | GSK3B (0.43) | GSK3BFBP1MEN1KMT2AFPR2 | |
| SCHEMBL5470802 | 0.72 | HCRTR2 (0.50) | GSK3BFBP1MEN1KMT2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | GSK3B 2540/4885FBP1 1879/4885MEN1 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.